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ABSTRACT
Background: Black box warnings indicating harmful or potentially fatal adverse events are required
by the Food and Drug Administration on certain drugs and chemical entities; however it is unclear if
prescribing and dispensing habits are impacted by these warnings. This study investigates the
knowledge and perceptions of prescribers and pharmacists regarding black box warnings.
Methods: A cross-sectional survey of self-reported behavior related to black box warnings was
administered to prescribers and pharmacists across North Carolina between October 2010 and
January 2011.
Results: A total of 867 pharmacists and prescribers completed the survey, including 715
pharmacists and 152 prescribers. Of the respondents, 54% were female and 92% described their
ethnicity as Caucasian. Overall, pharmacists reported a greater change in behavior than did
prescribers in relation to the presence of a boxed warning (P < .01). Pharmacists also demonstrated
a significantly greater overall knowledge of boxed warnings compared to prescribers (P < .01). No
differences in reported behavior or knowledge were observed between prescribers and pharmacists
_____________________________________________________________________________________________________
*Corresponding author: E-mail: richw@campbell.edu;
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based on demographic factors.
Limitations: Solicitation through professional association mailing lists resulting in low response
rates may impact findings.
Conclusion: Overall knowledge on information pertaining to boxed warnings was lacking. Impact in
clinical practice due to the lack of understanding regarding boxed warnings may put patients at
increased risk. To improve the overall knowledge of black boxed warnings, the FDA should adopt
develop a publicly available central repository for all black box warnings. Curricula in schools of
medicine and pharmacy as well as professional continuing education should include a focus on
boxed warnings.

Keywords: Boxed warning; drug regulation; labeling knowledge; prescribing behavior; dispensing
behavior.
drug with a boxed warning, with approximately 7
in 1000 outpatients receiving a prescription for a
drug that was in violation of the boxed warning.
It is unclear if prescribers are unaware of the
boxed warnings associated with these agents or
utilize clinical judgment to assess a specific
patient case.

1. INTRODUCTION
Boxed warnings, frequently called “Black Box
warnings”, are the strongest warning statements
that the Food and Drug Administration (FDA) can
require on a drug label [1]. These cautionary
statements are placed predominately on the
package insert and are called boxed warnings
because of the actual box that surrounds the
text. These warnings highlight potentially fatal or
disabling adverse events that are typically
identified from clinical data. However in the
absence of clinical data, serious animal toxicity
data may be utilized to support this cautionary
labeling [1]. The FDA provides guidance for
industry in conditions that may warrant a boxed
warning.
These
conditions
include
life
threatening adverse drug reactions and adverse
drug reactions that can be prevented or reduced
in frequency with appropriate drug use and
monitoring, or with restricted distribution or use
[2]. However, no clearly defined process or
criteria exists for applying these standards to
new drug applications or previously approved
products [3].

The number of boxed warnings utilized may
contribute to a lack of knowledge in healthcare
providers. According to a historical review of the
Physician’s Desk References published between
1975 and 2000, a total of 548 new chemical
entities were approved. Throughout this time
period, boxed warnings were added to 45
chemical entities (8.2%) after initial FDA
approval [2]. While these data do not include
boxed warnings that were part of the first
approved labeling, it does indicate frequent
addition of new warnings added after widespread
use.

1.1 Objective
The purpose of this cross-sectional study was to
examine the health care provider’s knowledge
and perception of boxed warnings and to
determine if behavior is affected by these
warnings.
The
self-reported
awareness,
perceptions, and impact of boxed warnings on
prescribing and dispensing habits of providers
was evaluated via an electronic survey.

The inclusion of a boxed warning, at approval or
post-marketing, is designed to make health care
providers aware of adverse events; however,
according to the published literature, prescriber
habits may or may not be affected by boxed
warning recommendations [4-13]. The postmarketing addition of boxed warnings for
antidepressants in pediatric and adolescent
patients, and the use of antipsychotics in
dementia patients caused a decline in the use of
these drug classes for these specific populations
[7-13]. Although some warnings result in a
decrease in prescribing habits, residual
inappropriate prescribing has been documented
after the addition of some boxed warnings [46,14-16] Lasser et al. [4], reported that 1 in 10
ambulatory patients was prescribed at least 1

2. METHODS
In 2010, a questionnaire (Fig. 1) was distributed
electronically via Zoomerang to all registered
pharmacists and prescribers in North Carolina
(NC) to evaluate the main outcome of self
reported behavior and knowledge related to
boxed warnings. All completed surveys from
October 26, 2010 to January 1, 2011 were
utilized in data analysis. In order to detect at
2
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least a 10% difference between groups at 80%
power with an alpha of .05 a sample of 540
participants
was
required.
Pharmacist
participants were recruited by email, via a list
maintained by the NC Board of Pharmacy, and
prescriber participants were recruited through a
postcard delivered by the US postal services.
The policy of the NC Board of Medicine
prevented email contact with prescribers, but did
allow the practice site mailing address to be
purchased from a public database of all NC
registered resident prescribers. The post card
containing a URL linking prescribers to the
survey was mailed to the address on file with the
NC Board of Medicine. The post card described
the study and invited prescribers to participate by
visiting the link. Prescribers included physicians,
physician assistants, and nurse practitioners.
Study participants completed the online survey
anonymously. Because the NC Board of
Pharmacy does not disclose individual email
addresses it was not possible to contact
pharmacist non-respondents. Similarly, post
cards sent out to prescribers did not contain a
unique identifier; therefore, prescriber nonrespondents could not be contacted. The
decision to exclude an unique identifier was
made by the research team in order to guarantee
anonymity of the respondents but also prevented
any utilization of incentives.

redirected to a brief message thanking them for
their time. All authors hereby declare that all
experiments have been examined and approved
by the university ethics committee (IRB) and
have therefore been performed in accordance
with the ethical standards laid down in the 1964
Declaration of Helsinki.

2.3 Survey Instrument
The survey questions were developed by the
research team based on a review of the
available literature and professional experience
of the pharmacists conducting the study.
Questions were reviewed by colleagues for face
validity, but pretesting was not performed.
The survey collected demographic information
regarding gender, ethnicity, years in practice,
and practice type for all participants (Fig. 1).
Pharmacists responded to a set of questions
regarding their opinion of the influence which
boxed warnings have on their practice.
Prescribers responded to a similar set of
questions regarding their opinion of the influence
which boxed warnings have on their practice. All
participants were asked to indicate how strongly
they agree with each of three statements
regarding the number of boxed warnings and the
number of chemical entities with boxed
warnings. For each of these statements
participants could rate their opinion on a 5-point
Likert scale. The scale consisted of the following:
“Strongly Agree (5)”, “Agree (4)”, “Neutral (3)”,
“Disagree (2)”, and “Strongly Disagree (1)”.

2.1 Data Sources
Several drug information databases were
queried in June 2010 for drugs containing a
boxed warning.
These databases included
Lexi-Comp, Facts and Comparisons, Clinical
Pharmacology,
Micromedex,
and
BlackBoxRX.com. All commercial products were
then grouped by active chemical entity.
Chemical entities no longer available in the
United States were excluded. The remaining
entities were then available for inclusion in the
survey.

Additionally all participants were asked to rate
their own awareness of boxed warnings using a
4-point Likert Scale consisting of the following
options: “Extremely Aware (4)”, “Very Aware (3)”,
“Somewhat Aware (2)”, and “Not at all Aware
(1)”. All participants also answered a total of 14
knowledge questions that related to the actual
number of chemical entities that possess boxed
warnings, the type of event that warrants a drug
or entity to receive a boxed warning, and the
identification of common drugs that currently
have a boxed warning.

2.2 Ethics Approval
Potential participants who were invited to
Participate in the study were provided with an
electronic informed consent statement before the
start of the survey. The informed consent
statement indicated that participation in this
study was completely voluntary and involved
minimal risk. To access the electronic survey
respondents were required to read and click
“agree” to the informed consent document.
Respondents who clicked “disagree” were

2.4 Analysis
For behavioral questions related to the influence
of boxed warnings (Fig. 1). The Likert-scale
scores for each participant were combined to
create a composite score ranging between 3 and
15. The composite score was then compared
between pharmacists and prescribers using an
3
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Informed Consent
Demographic information including location of practice (state, county,
rural or urban), years in practice, gender, and ethnicity.
Profession
Pharmacists

Prescribers

Practice Setting
(Hospital, Community Pharmacy-Independent,
Community Pharmacy-Chain, Clinic/Ambulatory Care,
Industry, Long Term Care, Academia, Other).

Practice Setting
(Hospital-Inpatient, Hospital-Emergency Medicine,
Clinic (ambulatory care, community health center,
outpatient), Private Practice, Other).

Behavioral Questions
5 point Likert ScaleStrongly Disagree (1) to Strongly Agree (5)
1) I use additional caution when dispensing or
recommending a drug with a boxed warning.
2) I perform a more intense drug utilization review
when dispensing or recommending a drug with a boxed
warning.
3) I do not do anything different or additional when
dispensing or recommending a drug with a boxed
warning.

Behavioral Questions
5 point Likert ScaleStrongly Disagree (1) to Strongly Agree (5)
1) When I am aware that a drug has a boxed warning
(“black box” warning), I use additional caution when
prescribing/using that drug.
2) When I am aware, I avoid using drugs with boxed
warnings (“black box” warnings).
3) The fact that a drug has a boxed warning (“black
box” warning) does not change how I prescribe/use that
drug.

Self-Rate Black Box Awareness
How would you rate your awareness of boxed warnings (“black box warnings”)?
[Not at all Aware (1), Somewhat Aware (2), Very Aware (3), Extremely Aware (4)]
Perception of Boxed Warnings
5 point Likert Scale Strongly Disagree (1) to Strongly Agree (5)- 1) Too many chemical entities have boxed
warnings. 2) An appropriate number of chemical entities have boxed warnings. 3) Not enough chemical
entities have boxed warnings.
Knowledge of Boxed Warnings
1) Which of the following would warrant a boxed warning (“black box” warning)? Answer Yes or No for
each. A) Death, B) Serious Injury, C) Animal toxicity in the absence of clinical toxicity date, D) Side
effects (serious adverse events) that are present in > 30% of the population, E) Unexplained side effects
(Serious Adverse Events).
2) How many chemical entities (active pharmaceutical ingredients) have a boxed warning? Select one.
A) 0 to 100, B) 101 to 350, C) 351 to 500, D) >500.
3) Which of the following drugs have a boxed warning? Answer Yes or No for each.
A) Alprazolam (Xanax), B) Atorvastatin (Lipitor), C) Fluoxetine (Prozac), D) Ibuprofen (Motrin), E)
Lisinopril (Zestril, Prinivil), F) Nifedipine (Adalat CC, Procardia), G) Tramadol (Ultram), H) Warfarin

Fig. 1. Survey instrument
independent samples t-test. Each participant’s
knowledge of boxed warnings was evaluated
through responses to questions in Fig. 1. Overall

knowledge scores were calculated as the
percent correct of the knowledge-based
questions and compared between pharmacists
4
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and prescribers using an independent samples ttest. One-way analysis of variance (ANOVA) was
used to evaluate differences regarding both
behavior and knowledge among prescriber
practice type and among pharmacist practice
type. P-values lower than 0.05 were considered
significant. A reliability analysis was conducted
for the behavioral questions (see Fig. 1) and a
Cronbach’s alpha of 0.87 was obtained
indicating sufficient internal reliability. Descriptive
statistics are provided for self-reported
awareness. All analyses were carried out using
SPSS/PASW 18.0. This study was approved by
the Institutional Review Board at Campbell
University College of Pharmacy & Health
Sciences.

as undeliverable. Of the pharmacists and
prescribers solicited 1,126 accessed the survey.
Of those who accessed the survey 77%
responded to the survey and provided main
outcome data related to behavior and knowledge
pertaining to boxed warnings (715 Pharmacists
and 152 prescribers) (Table 1). For the 867
respondents 54% were female, 46% were male,
92% described their ethnicity as Caucasian and
8% described themselves as non-Caucasian.

3.1 Prescribers and Pharmacists
An independent-samples t test was conducted to
evaluate the difference in reported behavior
between prescribers and pharmacists in relation
to the presence of a boxed warning (Table 2).
The test was significant, t(865) = 4.65, P < .01.
Pharmacists on average reported a significantly
greater change in behavior than did prescribers
when dealing with products with a boxed warning
(mean scores, 11.44 versus 10.34, respectively).
An independent samples t test was conducted to

3. RESULTS
Invitations to participate were mailed to 26,153
prescribers with 49 post cards returned as
undeliverable. Invitations to participate were
emailed to 9,873 pharmacists with 297 returned

Table 1. Demographic characteristics

Gender [No. (%)]
Women
Men
Race [No. (%)]
American Indian or Alaskan Native
Asian
Black or African American
Hispanic or Latino
Native Hawaiian or Other Pacific
Islander
White (Caucasian)
Pharmacist Practice Site [No. (%)]
Hospital
Community-Independent
Community-Chain
Clinic/Ambulatory Care
Industry
Long Term Care
Academia
Did Not Report
Prescriber Type [No. (%)]
Physician
Physician Assistant
Nurse Practitioner
Prescriber Practice Site [No. (%)]
Hospital-Inpatient
Hospital-Emergency Medicine
Clinic
Private Practice
Other

Pharmacists
415 (58)
300 (42)

Prescribers
50 (33)
102 (67)

Overall
465 (54)
402 (46)

7 (1)
29 (4)
14 (2)
0 (0)
0 (0)

1 (1)
7 (5)
10 (7)
4 (2)
0 (0)

8 (1)
36 (4)
24 (3)
4 (0)
0 (0)

665 (93)

130 (85)

795 (92)

201 (28)
103 (14)
202 (28)
52 (7)
45 (6)
26 (4)
17 (2)
69 (10)
117 (77)
34 (22)
1 (1)
23 (15)
12 (8)
38 (25)
61 (40)
18 (12)
5
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Table 2. Behavioral and perception questions mean scores

How many years have you been in practice?
Additional caution is used when dispensing/recommending/prescribing a drug with a
a
boxed warning.
I perform a more intense drug utilization review when dispensing or recommending a
a
drug with a boxed warning.
When I am aware, I avoid using drugs with boxed warnings (“black box” warnings).a
I do not do anything different or additional when dispensing/
a
recommending/prescribing a drug with a boxed warning.
Combined Score for Behavioral Questions
b
How would you rate your awareness of boxed warnings ("black box warnings")?
a
Too many chemical entities have boxed warnings.
a
An appropriate number of chemical entities have boxed warnings.
a
Not enough chemical entities have boxed warnings.

Pharmacists
Mean ± SD
(# of respondents)
18.99 ± 13.27 (715)
3.95 ± .89 (715)

Prescribers
Mean ± SD
(# of respondents)
20.31 ± 11.69 (152)
4.24 ± .81 (152)

P-value

3.76 ± .94 (715)

N/A

N/A

N/A
3.79 ± 1.07 (715)

2.66 ± 1.14 (152)
3.43 ± 1.14 (152)

N/A
<.01

11.44 ± 2.67 (715)
2.62 ± .64 (670)
3.18 ± .97 (670)
2.98 ± .87 (670)
2.54 ± .85 (670)

10.34 ± 2.49 (152)
2.63 ± .67 (144)
3.15 ± 1.05 (144)
2.94 ± .83 (144)
2.58 ± .90 (144)

< .01
.81
.78
.69
.55

Note: a. Responses,5-point Likert Scale; b. Responses, 4-point Likert Scale, N/A = Not Applicable

6

.26
< .01

Adams et al.; JAMPS, 15(1): 1-11, 2017; Article no.JAMPS.36666

evaluate the difference in overall mean score
for knowledge between pharmacists and
prescribers. Pharmacists demonstrated a
significantly greater overall knowledge [t(868) =
3.18, P < .01] of boxed warnings than did
prescribers (Table 3).

Community
Pharmacy
–
Independent,
Community Pharmacy – Chain, Hospital,
Clinic/Ambulatory Care, Long Term Care,
Industry. The dependent variable was the
composite score of reported behavior related to
boxed warnings. The ANOVA was not
significant.

No differences in either reported behavior or
knowledge were observed between prescribers
and pharmacists based on demographic factors
such as gender, ethnicity (white versus nonwhite), or location.

A one-way ANOVA was conducted to evaluate
the relationship between knowledge of boxed
warnings and practice type of pharmacists. The
independent variable, practice type, consisted of
seven levels: Academia, Community Pharmacy–
Independent, Community Pharmacy – Chain,
Hospital, Clinic/Ambulatory Care, Long Term
Care, Industry. The dependent variable was the
composite score for the knowledge questions.
The ANOVA was not significant. No differences
were observed regarding reported behavior and
demographic factors such as ethnicity or gender.

3.2 Among Prescribers
A one-way ANOVA was conducted to evaluate
the relationship between reported behavior
related to boxed warnings and practice type of
prescribers. The independent variable, practice
type, consisted of four levels: Hospital –
Inpatient, Hospital – Emergency Medicine, Clinic,
and Private Practice. The dependent variable
was the composite score of reported behavior
related to boxed warnings. The ANOVA was
significant, F(3, 130) = 2.977, P = .03.

4. DISCUSSION
Overall, knowledge of the justification and
requirements for a boxed warning, number of
chemical entities with a boxed warning, and
individual agents that have a boxed warning was
lacking. On the knowledge-based questions,
prescribers scored on average 56% while
pharmacists scored on average 59%, indicating
a gap in knowledge for both groups.

Pair-wise
comparisons
demonstrated the
differences among the means. Tukey post-hoc
analysis confirmed that prescribers who
indicated their practice type to be Hospital –
Emergency Medicine had a higher overall
composite score related to behavior than all
other practice types included in the study. The
95% confidence intervals as well as the means
and standard deviations for the practice types
are reported in Table 4.

An incomplete understanding of criteria for the
addition of a boxed warning to a chemical entity
related to significant animal toxicity, even in the
absence of human data, existed. Only 16% of
survey respondents identified the animal toxicity
as appropriate criteria for a boxed warning.
However, the recent approval of liraglutide
(Victoza – Novo Nordisk A/S) included a boxed
warning for increased risk of thyroid C-Cell
tumors that has only been observed in rodents
[17]. The human risk, although the extent is
currently unknown, was significant enough to
warrant this labeling.

A one-way ANOVA was conducted to evaluate
the relationship between knowledge of boxed
warnings and practice type of prescribers. The
independent variable, practice type, consisted of
four levels: Hospital – Inpatient, Hospital –
Emergency Medicine, Clinic, and Private
Practice. The dependent variable was the
composite score for knowledge of boxed
warnings. The ANOVA was not significant. No
differences were observed regarding reported
behavior and demographic factors such as
ethnicity or gender.

Wang et al. [18] evaluated the consistency of 3
commonly used databases in detecting an
interaction in drugs contraindicated to be used
concurrently. Each of the 3 interaction screening
databases reported less than half of the
expected interactions. The authors noted that
the information regarding severity and evidence
for
contraindicated
drug
combinations,
specifically addressed in boxed warnings, is
quite
variable
between
databases.
Inconsistencies between databases and product

3.3 Among Pharmacists
A one-way ANOVA was conducted to evaluate
the relationship between reported behavior
related to boxed warnings and practice type of
pharmacists. The independent variable, practice
type, consisted of seven levels: Academia,
7
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package inserts have also been documented
[19]. These inconsistencies may contribute to
lack of knowledge since many prescribers or
pharmacists typically have access to only one or
two databases in daily practice. A contributor to
this problem may be related to the lack of a FDA
maintained list of all drugs/entities with a boxed
warning.

increased potential of suicide in children and
adolescents on all antidepressants [20]. While
lay media coverage of boxed warnings may be
an avenue to communicate the risks, one study
indicates that FDA and lay media reports of
boxed
warnings
emphasized
different
information that is thought to be related to the
different reasons for reporting the information
[21]. These differences identified included an
under reporting in the lay media of the
generic names, research methods, clinical
recommendations, and instruction to seek health
care provider advice and an increased reliance
on expert testimonials and personal stories from
patients [21]. A similar effect attributed to the lay
press was documented in Moeller et al. [22] for
paroxetine and estrogen.

The two drugs in our survey that were most
frequently correctly identified by prescribers as
having a boxed warning were warfarin and
fluoxetine (78% and 74%, respectively; Table 3).
One reason for increased awareness for
fluoxetine may be related to the intense lay
media coverage of the announcement by the
FDA to include a boxed warning due to the

Table 3. Knowledge results

Which of the following would warrant a
boxed warning (“black box” warning)?
--Death a
a
--Serious Injury
--Animal toxicity in absence of clinical toxicity data a
--Side Effects (Serious Adverse Events) that are
present in >30% of the population
--Unexplained side effects (Serious Adverse Events)
How many chemical entities (active
pharmaceutical ingredients) have boxed warnings
(“black box” warnings)?
0 to 100
101 to 350
351 to 500 a
>500
Which of the following drugs have a boxed warning
(“black box” warning)?
Alprazolam (Xanax-Pfizer US Pharmaceutical Group)
Atorvastatin (Lipitor-Pfizer US Pharmaceutical Group)
Fluoxetine (Prozac-Eli Lilly & Co.) a
a
Ibuprofen (Motrin)
Lisinopril (Zestril-AstraZeneca, Prinivil-Merck Sharp &
a
Dohme)
Nifedipine (Adalat CC-Schering-Plough Corporation,
Procardia-Pfizer US Pharmaceutical Group)
Tramadol (Ultram-Janssen)
a
Warfarin (Coumadin-Bristol-Myers Squibb Company)
Overall Mean Percent Score ± SD
Total Complete Respondents

Pharmacists
no. (%)

Prescribers P-value
no. (%)

623 (93)
619 (92)
104 (15)
410 (61)

134 (93)
125 (87)
25 (17)
96 (67)

304 (45)

73 (51)

271 (40)
256 (38)
96 (14)
48 (7)

37 (25)
67 (47)
22 (15)
18 (12)

107 (16)
237 (35)
536 (80)
285 (42)
218 (32)

42 (29)
49 (34)
107 (74)
51 (35)
58 (40)

151 (23)

43 (30)

210 (31)
598 (89)
59 ± 13
671 (82)

62 (43)
113 (78)
56 ± 15
144 (18)

a Correct answer

8
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Table 4. Comparison of mean composite scores for reported behavior of prescribers by
practice type
Practice type

M

SD

Hospital-Emergency
Hospital-Inpatient
Clinic
Private Practice

12.42
10.09
10.24
10.16

2.43
2.25
2.67
2.47

Mean Diff.
(Hospital-Emergency)
a

2.33
2.18a
a
2.26

95% CI for Diff. of Means

.02-4.64
.03-4.33
.21-4.30

a

Note: P < .05

The effect caused by the existence of a boxed
warning is mixed. In a study conducted by
Lasser et al. [4], 7 out of 1000 outpatients
received a prescription drug in violation of a
boxed warning. However, an even higher rate of
non-compliance with boxed warnings has been
documented [14,16,23,24]. Of particular note are
studies that examine the contraindicated use of
metformin in patients with heart failure and/or
renal failure due to the increased risk of lactic
acidosis in this population [14,25,26]. Another
area of documented non-compliance with a
boxed warning occurred in the monitoring of
patients taking lithium, carbamazepine, and
valproate
[27].
However,
the
rate
of
antidepressant use in children did diminish after
the addition of a boxed warning to this class of
drugs [13]. Also, changes to the use of
antipsychotics in patients with dementia
decreased after the addition of a boxed warning
[10]. The reasons for non-compliance to a boxed
warning or the absence of change in usage after
the addition of a boxed warning are not known.
Our data indicate that there may be a lack of
knowledge of which agents have a particular
type of boxed warning and this may be related to
the large number of agents that include such a
warning and database inconsistencies. These
results suggest a need for additional black box
education in schools of medicine and pharmacy
in addition to professional continuing education
focused on boxed warnings. Another effort to
improve the overall knowledge of boxed
warnings would be one central repository for all
agents with boxed warnings. Consideration
should be given to prominence and consistency
of black box warning placement on literature
provided with all medications prescribed to
patients with additional information provided to
prescribers that describe the evidence base
which led to the boxed warning in the first place.
If prescribers and patients are able to
consistently find and review these warnings then
prescribers may consider alternative medications
in some instances. At the very least providing the
evidence base will allow prescribers to consider

appropriate prescribing
individual patient.

in

context

of

the

5. LIMITATIONS
The study is limited by the sample surveyed.
Only prescribers and pharmacists in NC were
recruited to participate. The inability to gain
direct access to respondent names and email
addresses prevented effective follow up for the
majority of the population solicited; therefore, a
follow up request and an evaluation of nonresponders was not possible. The inclusion of a
web link in the email solicitation to pharmacists
likely contributed to the stark contrast in
response rates (715 pharmacists vs. 152
prescribers). The extra step required for
prescribers to respond consisted of typing in a
web link from the post cards perhaps inhibiting
response rates in this group. Additionally, since
the respondents were utilizing the internet to
complete the survey, references could have
been used to assist with the completion of the
knowledge based questions. This could overestimate the mean knowledge scores of
participants. This study utilized self-reported
data, which may not translate into actual practice
behaviors. Formal pretesting was not performed
on the survey tool. The actual wording of survey
questions between prescribers and pharmacists
differed slightly, which may contribute to some of
the differences observed. Lastly, the small
proportion of prescriber respondents limits the
power of the analysis – particularly for sub-group
analysis.

6. CONCLUSION
Knowledge on justification and requirements for
a boxed warning, number of chemical entities
with a boxed warning, and individual agents that
have a boxed warning was deficient with a mean
score less than 60%. Low overall knowledge
may indicate a barrier to communicating the
purpose and reasoning for the addition of a
boxed warning to a drug label. Impact in clinical
9
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practice due to the lack of understanding
surrounding boxed warnings may put patients at
an increased risk for serious adverse reactions.
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